Molecular
diagnostics is a rapidly-advancing area of research and medicine, with
new technologies and applications being continually added. The
technologies that come under the umbrella of molecular diagnostics
include first-generation amplification, DNA probes, fluorescent in-situ
hybridization (FISH), second-generation biochips and microfluidics,
next-generation signal detection, biosensors and molecular labels, and
gene expression profiling using microarrays. These technologies are
improving the discovery of therapeutic molecules for cancer, the
screening, diagnosis and classification of cancer patients, and the
optimization of drug therapy. This Company Publications report describes
the specific segment of the in vitro diagnostics (IVD) market known as
molecular diagnostics (MD), with a specialization in the MD tests for
cancer. In the current medical diagnostics market, molecular diagnostics
for cancer testing offers one of the brightest areas for growth and
innovation. The confluence of breakthroughs in genomics, proteomics, and
the development of microarray devices to measure analytes in the blood
and various body tissues, has led to this revolutionary market segment
offering the power of advanced analytical techniques to the diagnosis
and treatment of cancer. This report analyzes the size and growth of the
molecular diagnostics market in its applications for cancer detection
and therapy, examining the factors that influence the various market
segments and the dollar volume of sales, both in the United States and
worldwide.
1. Overview 8
1.1 Statement of Report 8
1.2 About This Report 8
1.3 Scope of the Report 9
1.4 Objectives 9
1.5 Methodology 10
1.6 Executive Summary 11
2. Introduction to Molecular Diagnostics 15
2.1 Opening-up of Opportunities in Molecular Diagnostics 15
2.2 Impact of the Human Genome Project on Molecular Diagnostics 17
2.3 Considerations for Molecular and Clinical Diagnostics 17
2.4 Molecular Diagnostics in the Post-Genomic Era 20
2.5 Advances in Molecular Diagnostics Technologies 21
2.6 Oligonucleotide Array Platforms 23
2.7 Emerging Cancer Personalized Medicine Market 23
2.7.1 Predictive Cancer Molecular Diagnostics 25
2.8 Companion Tests for Drug Development 26
2.9 Opportunities for IVDMIA Companies 28
3. Cancer Diagnostics Molecular Testing Market 29
3.1 Market Description 33
3.1.1 Market Overview 33
3.1.2 Tumor Markers 34
3.1.3 Molecular Diagnostic Markers 40
3.1.4 Competitive Landscape 41
3.1.5 Sales and Marketing Strategies for Cancer Tests 44
3.1.5.1 North American Market 45
3.1.5.2 International Markets 46
3.1.5.3 Europe 46
3.1.5.4 Asia-Pacific 47
For more information, please visit:
http://www.aarkstore.com/reports/Molecular-Diagnostics-in-Cancer-Testing-82521.html
Or email us at press@aarkstore.com or call +919272852585
1. Overview 8
1.1 Statement of Report 8
1.2 About This Report 8
1.3 Scope of the Report 9
1.4 Objectives 9
1.5 Methodology 10
1.6 Executive Summary 11
2. Introduction to Molecular Diagnostics 15
2.1 Opening-up of Opportunities in Molecular Diagnostics 15
2.2 Impact of the Human Genome Project on Molecular Diagnostics 17
2.3 Considerations for Molecular and Clinical Diagnostics 17
2.4 Molecular Diagnostics in the Post-Genomic Era 20
2.5 Advances in Molecular Diagnostics Technologies 21
2.6 Oligonucleotide Array Platforms 23
2.7 Emerging Cancer Personalized Medicine Market 23
2.7.1 Predictive Cancer Molecular Diagnostics 25
2.8 Companion Tests for Drug Development 26
2.9 Opportunities for IVDMIA Companies 28
3. Cancer Diagnostics Molecular Testing Market 29
3.1 Market Description 33
3.1.1 Market Overview 33
3.1.2 Tumor Markers 34
3.1.3 Molecular Diagnostic Markers 40
3.1.4 Competitive Landscape 41
3.1.5 Sales and Marketing Strategies for Cancer Tests 44
3.1.5.1 North American Market 45
3.1.5.2 International Markets 46
3.1.5.3 Europe 46
3.1.5.4 Asia-Pacific 47
For more information, please visit:
http://www.aarkstore.com/reports/Molecular-Diagnostics-in-Cancer-Testing-82521.html
Or email us at press@aarkstore.com or call +919272852585
No comments:
Post a Comment